The International Association for the Study of Lung Cancer (IASLC) has published an updated consensus on the use of liquid biopsy in screening non-small cell lung cancer (NSCLC).
An updated consensus on liquid biopsy to detect non-small cell lung cancer (NSCLC) use has been published by the International Association for the Study of Lung Cancer (IASLC).1
The statement argues that liquid biopsy is now a favored method of molecular testing in various clinical settings and that it has demonstrated that it is effective in conjunction with tumor tissue testing.2 In addition, liquid biopsy offers unique opportunities such as serial monitoring and detection of minimal residual disease, according to the statement. Going forward, the IASLC expects a significant increase in the use of liquid biopsy.
The report discusses the inherent limitations of tumor tissue testing, which has traditionally been considered the gold standard for molecular analyses and argues that liquid biopsy approaches allow more varied methods of circulating analytes. According to the report, plasma circulating tumor DNA (ctDNA) represents the most widely studied and generally accepted alternative to tumor genotyping in solid tumors, including NSCLC.
“It is notable that the IASLC has taken the lead in detailing the current state of the art in this rapidly expanding field,” stated Gandara, MD, director of thoracic oncology, professor of medicine emeritus, in a news release. “Non-small cell lung cancer, in particular, is an ideal disease area for application of liquid biopsy due to the increasing availability of targeted therapies for this genomically complex malignancy. Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is not applicable, such as the detection of minimal residual disease (MRD).”
The report builds upon a statement released by the IASLC in 2018 and was coauthored by a group of distinguished international lung cancer clinicians and experts.
In the report, the recommendations are as follows:
The 2021 World Conference on Lung Cancer, which will be held this upcoming September, will present a series of abstracts related to liquid biopsy methodologies and offer information regarding lung cancer screening, diagnoses, and therapeutic efficacy.
IASLC issues consensus updated report on liquid biopsies. IASLC. Press release. July 8, 2021.
Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl
L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani
C, Mitsudomi T, Gandara D, Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC), Journal of Thoracic Oncology (2021), doi: https://doi.org/10.1016/j.jtho.2021.06.017.